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Abstract
Background: Neurocysticercosis is endemic in most countries of Central and South America but has rarely been
described in the French West Indies. We aimed to better understand the clinical and radiological presentation of
our cases.
Case presentation: We report three cases of neurocysticercosis in patients living in Guadeloupe, with different
clinical and radiological presentations.
Conclusion: Given the eventuality of autochtonous transmission, the diagnosis should be considered in all patients
living in Guadeloupe presenting with seizures.
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Background
Neurocysticercosis (NCC) constitutes the most frequent
parasitic infection of the nervous system [1]. NCC is the
expression of the neurological stage of infestation by
Taenia solium pork tapeworm larvae, when humans
become accidental dead-end hosts of the parasitic cycle.
Disease results from ingestion of T. solium eggs shed in
the stool of a human tapeworm carrier. The embryos are
released from the egg in the intestines after ingestion
and cross the intestinal mucosa toward the bloodstream,
which carries them to peripheral tissues including the
central nervous system (CNS), where they develop into
cysticerci [2]. Lesions are predominantly intracranial
although there are other predilection sites like ophthal-
mic localizations and muscular calcifications [2]. Most
of the neurological infections are asymptomatic, how-
ever when symptoms are present, seizures are the most
common manifestation of the disease, although head-
aches, neurological deficits, intracranial hypertension,
cerebrovascular complications are also reported [2].
NCC is endemic in many tropical countries [3–7].
Numerous imported cases have been described in
Western Europe and North America [2]. In France,
67 cases have been reported from 1970 to 2013, most
of them thought to be imported from endemic areas [8].
In Haiti and bordering areas of the Dominican Republic,
seroprevalence of cysticercosis has been estimated to be
around 3% [9–11]. To our knowledge, only four cases
diagnosed in the French West Indies had been reported
previously in the literature [12, 13].
We report on three additional cases of NCC diagnosed
over a 2 month period in Guadeloupe, French West
Indies, and discuss each particular clinical and radio-
logical presentation.
Case presentation
Clinical and radiological presentations are summarized
in Table 1.
Case 1
A 25-year-old Dominican woman with no medical
history was admitted to the department of infectious
diseases at Pointe-à-Pitre University hospital with tonic-
clonic generalized seizures. She had been living in
Guadeloupe for 1 year, had never left the Dominican
Republic before moving to Guadeloupe and had never
had any focal neurological sign nor seizure before. Brain
computed tomography (CT) showed multiple brain
lesions consisting of calcified cysts and magnetic reson-
ance imaging (MRI) showed one postero-frontal cyst
sheltering a scolex at vesicular stage (Fig. 1a), which
fulfilled the diagnosic criteria for definite NCC [14, 15].
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Another lesion was surrounded by parenchymal edema,
reflecting degenerative changes observed in NCC at the
colloidal stage (Fig. 1d). Fundus evaluation was normal
and no extraneural localization was clinically found. X ray
of legs and arms showed no extraneural “cigar shaped
calcification” in muscles or soft tissues. The detection
of anticysticercal antibodies by serum enzyme-linked
immunosorbent assay (ELISA) (EIA IBL-Diasorin®)
was negative. CSF analysis showed no abnormality (2
WBC/mm3, normal proteins = 0.46 g/L, normal glu-
cose level = 3.3 g/L in CSF and 4.3 g/L in blood,
negative bacterial culture) and enzyme-linked immu-
noelectrotransfer blot (EITB) assay for detection of
antibodies to T. solium glycoprotein antigens on CSF
Table 1 Clinical, biological and radiological characteristics of the patients
Patient 1 Patient 2 Patient 3
Origin Dominican Republic Haiti Haiti
Age (years) 25 52 41
Sex (W/M) W W M
Date of diagnosis (and onset of symptoms) December 2014 January 2015 December 2014
Time in Guadeloupe 1 year 10 years Several years
Initial symptoms Generalized seizure Generalized seizure Ischemic stroke and
tonic-clonic seizuresa
Number of colloidal cysts 1 5 0
Number of vesicular cysts 1 1 0
Number of calcified cerebral cysts 3 9 30
T. solium antibodies in serum (ELISA) Negative Negative Negative
T. solium antibodies in CSF (EITB) Negative Positive Not done
Screening for taeniasis in index case Negative Negative Negative
Screening for taeniasis in household Negative Negative Negative
Treatment Albendazole + Steroids +
Valproic acid
Albendazole + Praziquantel
+ Steroids + Levetiracetam
Surgical removala +
Albendazole + Steroids +
Valproic acid
Seizure recurrence in the first 6 months
after treatment
Several Multiple episodes in the first
months after tapering steroids
No recurrence




Fig. 1 Brain MRI of patient 1 before and after treatment. a FLAIR sequence, cysticercus scolex at vesicular stage before treatment; b FLAIR
sequence, scolex surrounded by edema after treatment; c T1 sequence with gadolinium after treatment, single enhancing lesion of scolex at
vesicular stage; d FLAIR sequence, edema consistent with cysticercus cyst at colloidal stage before treatment, e FLAIR sequence, persisting lesion
without edema after treatment
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was negative (LDBIO diagnostics®). Stool specimen
examination for T. solium eggs by microscopy was
negative for our patient and all members of her
household. No EEG was performed before treatment.
She was treated with antiepileptic (valproic acid
500 mg twice daily) and anti-parasitic therapy (alben-
dazole 400 mg twice daily for 14 days) with an adju-
vant 14-day dose-reducing course of corticosteroids
(dexamethasone 7 mg (0.1 mg/kg) a day for 3 days,
then prednisone 70 mg a day for 7 days, then 30 mg
for 4 days) [16]. The patient suffered from several
focal seizures (clonic movement of the lower leg with-
out impairment of consciousness) with no focal
neurological deficit after tapering out cortisone and a
generalized seizure 6 month after initiation of treat-
ment. Control MRI at 6 months showed degeneration
of the cysts (Fig. 1b, c and e), control EEG was nor-
mal but valproate dose was increased to avoid further
seizures. At 9 months of follow-up, neurological
examination was normal without further seizure activ-
ity with 2000 mg per day of valproic acid.
Case 2
A previously healthy 52-year-old Haitian woman was ad-
mitted to the department of infectious diseases of our
institution with a generalized tonic-clonic seizure and
transient stupor with no focal neurological deficit. She
had never had any seizure before but complained of
recurrent headaches. She had been living in Guadeloupe
for 10 years and had never traveled abroad before and
after moving from Haiti. She had no precipitating factor
for seizures. CT of the brain showed multiple nodular
calcifications in both hemispheres (Fig. 2a and b). MRI
showed one right parietal cyst at vesicular stage with
vasogenic edema (Fig. 2c) and various at colloidal stage,
which fulfilled the diagnosis criteria for definite NCC
[14, 15]. Fundoscopy was normal. Extraneural localisa-
tions were excluded by X ray of legs and arms. The
detection of anticysticercal antibodies by ELISA (EIA
IBL-Diasorin®) was negative on serum. CSF biochemical,
cytological, and microbiological examinations were
normal (no WBC, normal protein level (0.22 g/L),
normal glucose level (3.7 g/L in CSF versus 4.4 g/L in
blood), negative bacterial culture) but EITB for detection
of antibodies to T.solium glycoprotein antigens per-
formed on CSF (LDBIO diagnostics®) was positive for
anti-p23-26 and anti-p39 antibodies. No evidence of
taeniasis was found by microscopy in any of the stool
specimens from the patient or her son.
She was treated with a combination of albendazole
(400 mg twice daily for 14 days) and praziquantel (1 g
three times daily) for 14 days, with dexamethasone
started on the same day (6 mg a day for 3 days, then
prednisone 40 mg a day for 3 days then 20 mg a day for
4 days) and levetiracetam (500 mg twice daily). A few
weeks after tapering out corticosteroids she showed
symptoms of focal seizures with daily paresthesia of her
left foot and hand that resolved a few weeks after in-
creasing levetiracetam to 1500 g a day. Control MRI
after 3 months of treatment showed edema replacing the
right parietal cyst. Calcified and colloidal lesions
remained stable (Fig. 2d), control EEG was normal.
Case 3
A 41-year-old Haitian male with no medical history was
admitted to the department of neurology of our institu-
tion with right sudden hemiplegia, aphasia and fever and
a possible tonic-clonic seizure witnessed by his family.
He had been living in Guadeloupe for several years and
had not travelled abroad before and after moving from
Haiti. He had no previous medical history, in particular
no risk factor for stroke. Brain CT showed a left middle
cerebral artery infarct secondary to an occlusion of the
left internal carotid artery with mass effect. It also
revealed multiple supratentorial intraparenchymal and
subarachnoid hyperdense homogenous round shaped
and infracentimetric lesions in the parietal, frontal, tem-
poral and occipital lobes, consistent with calcified NCC
(Fig. 3a). No active lesion was found by CT-scan nor
MRI. Duplex ultrasound of supra-aortic vessels showed
no cervical arteriosclerosis, the distal left internal carotid
was not visible and the signal of the common carotid
artery was more restrictive (0.81 vs 0.64) which was





Fig. 2 Brain CT and MRI of patient 2 before and after treatment. a and
b Brain CT, multiple calcified cysts before treatment with two probably
physiological falx calcifications (discontinued arrow); c MRI, FLAIR
sequence, cysticercus scolex at vesicular stage before treatment; d
FLAIR sequence, cyst replaced by edema after treatment
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ultrasound showed increased velocities of the left me-
dian (111 cm/s), posterior (174 cm/s) and anterior
(101 cm/s) arteries and of the right anterior (158 cm/s)
and posterior (114 cm/s) arteries consistent with the
presence of a posterior communicating artery or with
angiitis. The left anterior cerebral artery had a retrograde
flow, which was consistent with the presence of a poster-
ior communicating artery. CT- angiography (cf Additional
file 1) showed an expanded diameter of the internal
carotid artery probably due to a thickening of the arterial
wall and irregularity of the lumen on its initial portion
consistent with a dissection. No fat saturated T1 axial
image was performed on MRI to confirm the dissection.
Left craniectomy was performed to decrease intracranial
hypertension due to cerebral ischemia. During craniect-
omy, no ischemic tissue was excised but two subarachoi-
dal cysts were discovered and removed. Pathological
examination of one cyst showed a round-shaped infracen-
timetric (0.8× 0.3 cm) structure made of a fibrous shell
sheltering an invaginated scolex with intestinal microvill-
osities and eosinophilic infiltrate consistent with colloidal
stage larvae (Fig. 4) which fulfilled the diagnosic criteria
for definite NCC [14, 15]. No PCR for T. Solium was
performed on the cyst. Fundoscopy was normal. No extra-
neural lesion was found on X ray of legs and arms. The
detection of anticysticercal antibodies by serum ELISA
(EIA IBL-Diasorin®) was negative and CSF was not tested.
Stool examination for T. solium by microscopy was nega-
tive in the patient but screening of members of his house-
hold could not be performed.
Following craniectomy, the patient partially recovered
from neurological damage with persisting spastic right
hemiplegia and both receptive and expressive aphasia.
He was given a 14-day regimen of albendazole (400 mg
bid) starting 10 days after surgery, when CT-scan
showed a resolution of cerebral edema. This choice was
justified by the presence of active lesions inside of the
stroke as demonstrated by the presence of living larvae
at pathological examination [16]. This treatment was
administered along with corticosteroids (1 mg/kg/day
for 3 days, rapidly tapered during 6 days) and valproic
acid (500 mg twice daily), with no subsequent recurrence
of seizures.
Discussion
Our three cases illustrate three distinct clinical stages
and a variety of radiological presentations of the disease
(Table 1). All of them were foreigners, coming from
areas of higher endemicity, they all had only intracranial
manifestations with variability in the number of cysts,
and with seizures in the first two cases and probably in
the third case.
Our three patients all fulfilled absolute or major clin-
ical, radiological and/or serological criteria for NCC:
histological demonstration of the parasite (Patient 3),
evidence of cystic lesions showing the scolex (Patient 1
and 2), positive CSF immunoblot for the detection of
anticysticercal antibodies (Patient 2), and resolution of
a b
Fig. 3 Brain CT of patient 3 before and after treatment. a Contrast-enhanced CT, calcified parenchymatous and subarachnoid cysticercus cysts
within ischemic territory; b Calcified cysts within ischemic territory after craniectomy
Fig. 4 Cross section of a cyst extracted from the brain of the patient
3, stained with H and E at × 40 magnification
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intracranial cystic lesions after therapy with albendazole
(Patient 1 and 2) [14, 15]. Real time PCR (Polymerase
chain reaction) for T. solium in CSF can be helpful when
the diagnosis is uncertain (sensitivity 83.3%, specificity
100% [17]) but we did not have to perform it because our
patients all fulfilled criteria for definite NCC.
Their clinical presentation was slightly different from
previous case reports from Guadeloupe [12, 13]. To
date, only four other cases have been reported in
Guadeloupe in the late nineties. Three of them had
intracranial parenchymatous NCC and one had cysticer-
cosis outside CNS, all confirmed by either serology,
pathognomonic images on CT scan [12] or histology
[13] (MRI was not avalaible at that time in Guadeloupe).
Three (1 man, 2 woman) had seizures like our cases,
among them one woman had subacute meningitis (180
cells/mm3 in CSF and proteins = 0.6 g/L). The last one
(child) had a periorbital intramuscular nodule. Two of
them were middle-aged women originating from Haiti
where they were probably contaminated as for two of
our cases. The man, who was born and lived in
Guadeloupe, might have been infected abroad as it was
reported that he traveled frequently, and the child had
probable autochtonous transmission because he had
never left Guadeloupe [12, 13]. More information is
missing to better compare them to our cases.
Cerebrovascular and particularly ischemic complica-
tions of NCC, are well documented (between 4% and
12% of patients with NCC according to different studies
[18, 19]). Chronic subarachnoid inflammation creates
angiitis with progressive stenosis, sometimes leading to
the occlusion of one or several cerebral arteries [20, 21].
However in patient 3, we cannot draw any causal rela-
tionship between the stroke and NCC. The stroke was
most probably rather due to the dissection of the left in-
ternal carotid artery.
All patients with NCC should receive symptomatic
treatment, which consists of antiepileptic medication for
patients with seizures, analgetics for patients with pain
and corticosteroids for patients with increased intracra-
nial pressure or encephalitis [2]. Antiparasitic treatment
should be adapted based on findings from neuroimaging
[2, 16], including the localization, number and stage of
cysts, and the presence of intracranial hypertension.
Different options exist including no antiparasitic treat-
ment, albendazole, praziquantel or both in combination
with corticosteroids, and surgical treatment.
In patients with only calcified lesions, antiparasitic
treatment has not shown any benefit [16]. For patient 3,
despite the presence of only calcified lesions on CT scan,
we decided to treat with albendazole, because of the
presence of living larvae at pathological examination. In
patients with active cysts, albendazole in combination
with corticosteroids offers a reduction in the number of
generalized seizures in the years following initiation of
treatment and the duration of seizure risk compared
with placebo [22, 23].
The association of both albendazole and praziquantel
has recently shown to increase the parasiticidal effect in
patients with multiple viable intraparenchymal cysts
[24]. This is why it was used on patient 2.
Patients 1 and 2 experienced several relapses, with
partial seizures shortly after treatment initiation despite
significant resolution of the cysts as shown on repeat
MRI (Fig. 1b, c, e, Fig. 2b and d). The rate of seizure
recurrence in the first 12 month after treatment with
albendazole is approximately 40% [22, 25]. Inflammation
after cyst degeneration with albendazole [2] can be
responsible for seizures but is an indicator of efficient
cure [26]. Drug-drug interactions between some antiepi-
leptics and albendazole or praziquantel might be a
source of antiparasitic treatment failure and a source of
persisting seizures [27]. Seizures prior to therapy, per-
sistence of active or calcified lesions on radiological
follow-up [22], family history of seizures, serial seizures
and electroencephalographic abnormalities [28] have all
been described as risk factors for seizure recurrence.
There is no clear recommendation in the length of treat-
ment with steroids, but patient 1 and 2 could have bene-
fitted from a longer course on the seizure recurrences.
All three patients had multiple lesions, in common
with most cases in adults from endemic areas and par-
ticularly in South America; a single enhancing lesion is
the most frequent finding in children and in India,
where the parasitic load is lower [2, 29].
The three cases described here were probably imported.
Patient 1 had most likely the most recently acquired the
infection, as indicated by her young age, the CT findings
[15, 30, 31], and the fact that she lived in an area of NCC
endemicity until 1 year before her first symptoms. Patient
2 suffered from a later stage of the disease and had prob-
ably contracted it in Haiti more than 10 years before.
Patient 3 is a vivid illustration of a disseminated NCC that
had remained clinically dormant for a long time.
In endemic areas clusters of swine cysticercosis have
been described around human carriers and justify inter-
ventions for control and elimination in humans [32]. In
high-income countries transmission from pig-to-human
is unlikely due to better human hygiene and veterinary
standards of the pigs [33]. T. solium eggs have never
been found in water or soil [8, 9], however NCC has
frequently been imported by tapeworm carriers into
non-endemic countries [5]. This confirms that humans
can be a reservoir of the disease and that cysticercosis
transmission does not require the presence of infected
pigs [34]. One case of autochthonous acquisition has
already been described in Guadeloupe, in a child who had
never left the island and presented with a extracerebral
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form of the disease (periorbital intramuscular nodule)
[13]. Clusters of humans with positive T. solium serology
have been described around tapeworm carriers, but no
cluster of cases of NCCs was seen [35]. As epilepsy due to
NCC appear late in the history of the infection, it is not
routinely diagnosed around tapeworm carriers [2]. Con-
current intestinal taeniasis is reported in around 5% of the
patients with cysticercosis [2, 36, 37]. These patients usu-
ally present with a more severe cerebral infection due to
repeated auto-infection [2].
We failed to identify tapeworm carriage in our neuro-
cyticerosis patients or those in their households, prob-
ably because we used direct examination of stool, which
is suboptimally sensitive. Specific coproantigen detection
by ELISA assays [38] is more sensitive and could more
efficiently detect carriers who would be eligible for treat-
ment with niclosamide to prevent transmission [2, 38].
Conclusion
NCC should be suspected in patients originating from
endemic areas who present with headaches, epileptic
seizures or neurovascular symptoms.
Given the possibility of autochthonous transmission in
Guadeloupe, it should also be considered in patients
who have never traveled to endemic areas, especially
when they live among communities with a high preva-
lence of NCC. Those communities could be responsible
for a cluster of cases. A cross-sectional survey to deter-
mine prevalence of T. solium seropositivity could be very
usefull to assess the risk of transmission in Guadeloupe.
Additional file
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